Iran's Approach to COVID-19: Evolving Treatment Protocols and Ongoing Clinical Trials
- PMID: 33014984
- PMCID: PMC7498537
- DOI: 10.3389/fpubh.2020.551889
Iran's Approach to COVID-19: Evolving Treatment Protocols and Ongoing Clinical Trials
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is challenging the health care systems around the world and compelling them to timely share their strategies, tactics and experiences. Since mid-January, a huge volume of instructions has been released by Iran's Ministry of Health and Medical Education (MOHME) covering diverse aspects of disease control and prevention. In this study, we aimed to review the instructions published either before or after COVID-19's transmission to Iran to depict the clinical approach and therapeutics used in Iran to battle the current pandemic. We retrospectively gathered and critically reviewed all official situation reports, guidelines, guidance, flowcharts, protocols, recommendations and advice released by Iranian scientific, or administrative arms of action against COVID-19. The ongoing clinical trials approved by MOHME and registered to the Iranian Registry of Clinical Trials (IRCT) have been reviewed as well. Our study resulted in the following mainstays of Iran's approach to COVID-19: (i) active clinical screening; preferably on-line or on-phone, (ii) management of limited paraclinical resources; by using them as diagnostic tools rather than epidemiological, (iii) a trend toward outpatient care of mild-to-moderate cases; either confirmed or suspicious, with active scheduled follow-up, and (iv) avoidance of pharmacotherapy, as far as possible. The therapeutic and administrative instructions are still being actively updated with some recommendations different from the previous ones. Nevertheless, a common approach in the background could be detected, It seems that the instructions are conceptually in line with the first "National Guideline for 2019-nCoV" published on 20 January 2020. The screening has mainly been clinically oriented rather than being based on laboratory tests and MOHME seems to be following the approach of "early detection of symptomatic cases followed by early source control."
Keywords: COVID-19; Iran; SARS-CoV-2; antiviral therapy; infection prevention and control; public health.
Copyright © 2020 Rahmanzade, Rahmanzadeh, Hashemian and Tabarsi.
Figures
Similar articles
-
Toward an Agile System: Iranian Information System for Covid-19-Affected Patients Data Collection from Iranian Hospitals.Stud Health Technol Inform. 2021 Oct 27;285:173-178. doi: 10.3233/SHTI210593. Stud Health Technol Inform. 2021. PMID: 34734870
-
Provision of Critical Maternity Care during the Coronavirus Disease 2019 (COVID-19) Pandemic in the Islamic Republic of Iran.Arch Iran Med. 2020 Aug 1;23(8):557-560. doi: 10.34172/aim.2020.59. Arch Iran Med. 2020. PMID: 32894968
-
Iran, sanctions, and the COVID-19 crisis.J Med Econ. 2020 Dec;23(12):1461-1465. doi: 10.1080/13696998.2020.1856855. Epub 2020 Dec 16. J Med Econ. 2020. PMID: 33249954
-
Human and novel coronavirus infections in children: a review.Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25. Paediatr Int Child Health. 2021. PMID: 32584199 Review.
-
COVID-19 outbreak control, example of ministry of health of Turkey.Turk J Med Sci. 2020 Apr 21;50(SI-1):489-494. doi: 10.3906/sag-2004-187. Turk J Med Sci. 2020. PMID: 32304192 Free PMC article. Review.
Cited by
-
Efficacy and Safety Comparison of Two Different Doses of Dexamethasone in Hospitalized Patients with COVID-19: A Randomized Clinical Trial.J Res Pharm Pract. 2023 Aug 29;11(4):136-143. doi: 10.4103/jrpp.jrpp_42_22. eCollection 2022 Oct-Dec. J Res Pharm Pract. 2023. PMID: 37969616 Free PMC article.
-
Study Factors Involved in Maternal Deaths Attributed to COVID-19 in a Disadvantaged Area in Southeast of Iran.J Family Reprod Health. 2022 Mar;16(1):67-77. doi: 10.18502/jfrh.v16i1.8596. J Family Reprod Health. 2022. PMID: 35903768 Free PMC article.
-
Combined systemic inflammatory indexes as reflectors of outcome in patients with COVID‑19 infection admitted to ICU.Inflammopharmacology. 2023 Oct;31(5):2337-2348. doi: 10.1007/s10787-023-01308-8. Epub 2023 Aug 7. Inflammopharmacology. 2023. PMID: 37550520
-
Efficacy and Safety of Inhalation of Nebulized Ethanol in COVID-19 Treatment: A Randomized Clinical Trial.Cureus. 2022 Dec 5;14(12):e32218. doi: 10.7759/cureus.32218. eCollection 2022 Dec. Cureus. 2022. PMID: 36505954 Free PMC article.
-
Aryl-hydrocarbon receptor dysregulation and its correlation with immunomodulatory markers in COVID-19 patients.Inflammopharmacology. 2025 Jul;33(7):4115-4124. doi: 10.1007/s10787-025-01828-5. Epub 2025 Jul 1. Inflammopharmacology. 2025. PMID: 40591212
References
-
- WHO Timeline-COVID-19. Available online at: https://www.who.int/news-room/detail/08-04-2020-who-timeline---covid-19.
-
- Iran's National Guideline for 2019-nCoV; 1st edition Available online at: https://firoozgar.iums.ac.ir/files/baharestan/files/dam.pdf.
-
- Iran's National Guideline for 2019-nCoV; 2nd edition Available online at: https://firoozgar.iums.ac.ir/files/baharestan/files/kesh.pdf.
-
- WHO's Situation Report-30 Available online at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/2....
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous